[1,3,5]Triazine-pyridine Biheteroaryl
Journal of Medicinal Chemistry, 2005, Vol. 48, No. 14 4545
(4) Sielecki, T. M.; Boylan, J. F.; Benfield, P. A.; Trainor, G. L.
Cyclin-dependent kinase inhibitors: Useful targets in cell cycle
regulation. J. Med. Chem. 2000, 43, 1-18.
(5) (a) Nikolic, M.; Tsai, L. H. Activity and regulation of p35/cdk5
kinase complex. Methods Enzymol. 2000, 325, 200-213. (b)
Maccioni, R. B.; Otth, C.; Concha, I. I.; Munoz, J. P. The protein
kinase cdk5. Structural aspects, roles in neurogenesis and
involvement in Alzheimer’s pathology. Eur. J. Biochem. 2001,
268, 1518-1527.
(15) No structure available. Siemeister, G.; Briem, H.; Brumby, T.;
Haberey, M.; Hess-Stumpp, H.; Jautelat, R.; Kruger, M.; Luck-
ing, U.; Reichel, A.; Schafer, M.; Bosslet, K. The dual-specific
CDK2/VEGF-RTK inhibitor ZK-CDK potently inhibits prolif-
eration of human tumor cells, induces apoptosis, and inhibits
growth of human xenograft tumors. Proc. Am. Assoc. Cancer Res.
2004, 45, Abst 829.
(16) Harris, R. L. N. The synthesis of triazines from N-cyano-
carbamimidates. Synthesis 1981, 907-908.
(6) Napolitano, G.; Majello, B.; Lania, L. Role of cyclinT/cdk9
complex in basal and regulated transcription (Review). Int. J.
Oncol. 2002, 21, 171-177.
(7) (a) Garrett, M. D.; Fattaey, A. CDK inhibition and cancer
therapy. Curr. Opin. Genet. Dev. 1999, 9, 104-111. (b) Meijer,
L.; Leclerc, S.; Leost, M. Properties and potential applications
of chemical inhibitors of cyclin-dependent kinases. Pharmacol.
Ther. 1999, 82, 279-284.
(17) Reisch, J.; Dziemba, P.; Mura, M. L.; Rao, A. R. R. Natural
product chemistry. part 159 [1]. Two methods for the synthesis
of 4-azaacronycine as a potential antitumor agent. J. Heterocycl.
Chem. 1993, 30, 981-983.
(18) Fujita, M.; Oka, H.; Ogura, K. Palladium(0)/LiCl promoted cross-
coupling reaction of (4-pyridyl)stannanes and aromatic bro-
mides: easy access to poly(4-pyridyl)-substituted aromatics.
Tetrahedron Lett. 1995, 36, 5247-5250.
(8) (a) Senderowicz, A. M. Modulators of cyclin-dependent kinases:
a novel therapeutic approach for the treatment of neoplastic
diseases. Cell Cycle Inhib. Cancer Ther. 2003, 179-205. (b)
Wang, S.; Meades, C.; Wood, G.; Osnowski, A.; Anderson, S.;
Yuil, R.; Thomas, M.; Mezna, M.; Jackson, W.; Midgley, C.;
Griffiths, G.; Fleming, I.; Green, S.; McNae, I.; Wu, S.-Y.;
McInnes, C.; Zheleva, D.; Walkinshaw, M. D.; Fischer, P. M.
2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: Synthesis,
SAR analysis, X-ray crystallography, and biological activity. J.
Med. Chem. 2004, 47, 1662-1675. (c) Nugiel, D. A.; Vidwans,
A.; Etzkorn, A.-M.; Rossi, K. A.; Benfield, P. A.; Burton, C. R.;
Cox, S.; Doleniak, D.; Seitz, S. P. Synthesis and evaluation of
indenopyrazoles as cyclin-dependent kinase inhibitors. 2. Prob-
ing the indeno ring substituent pattern. J. Med. Chem. 2002,
45, 5224-5232. (d) Yue, E. W.; Higley, C. A.; DiMeo, S. V.;
Carini, D. J.; Nugiel, D. A.; Benware, C.; Benfield, P. A.; Burton,
C. R.; Cox, S.; Grafstrom, R. H.; Sharp, D. M.; Sisk, L. M.;
Boylan, J. F.; Muckelbauer, J. K.; Smallwood, A. M.; Chen, H.;
Chang, C.-H.; Seitz, S. P.; Trainor, G. L. Synthesis and evalu-
ation of indenopyrazoles as cyclin-dependent kinase inhibitors.
3. Structure activity relationships at C3. J. Med. Chem. 2002,
45, 5233-5248. (e) Zhu, G.; Conner, S. E.; Zhou, X.; Shih, C.;
Li, T.; Anderson, B. D.; Brooks, H. B.; Campbell, R. M.;
Considine, E.; Dempsey, J. A.; Faul, M. M.; Ogg, C.; Patel, B.;
Schultz, R. M.; Spencer, C. D.; Teicher, B.; Watkins, S. A.
Synthesis, structure-activity relationship, and biological studies
of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J. Med.
Chem. 2003, 46, 2027-2030. (f) Markwalder, J. A.; Arnone, M.
R.; Benfield, P. A.; Boisclair, M.; Burton, C. R.; Chang, C.-H.;
Cox, S. S.; Czerniak, P. M.; Dean, C. L.; Doleniak, D.; Grafstrom,
R.; Harrison, B. A.; Kaltenbach, III, R. F.; Nugiel, D. A.; Rossi,
K. A.; Sherk, S. R.; Sisk, L. M.; Stouten, P.; Trainor, G. L.;
Worland, P.; Seitz, S. P. Synthesis and biological evaluation of
1-aryl-4,5-dihydro-1H-pyrazolo[3, 4-d]pyrimidin-4-one inhibitors
of cyclin-dependent kinases. J. Med. Chem. 2004, 47, 5894-
5911. (g) Schoepfer, J.; Fretz, H.; Chaudhuri, B.; Muller, L.;
Seeber, E.; Meijer, L.; Lozach, O.; Vangrevelinghe, E.; Furet, P.
Structure-based design and synthesis of 2-benzylidene-benzo-
furan-3-ones as flavopiridol mimics. J. Med. Chem. 2002, 45,
1741-1747.
(19) Littke, A. F.; Dai, C.; Fu, G. C. Versatile catalysts for the suzuki
cross-coupling of arylboronic acids with aryl and vinyl valides
and triflates under mild conditions. J. Am. Chem. Soc. 2000,
122, 4020-4028.
(20) Hargreaves, S. L.; Pilkington, B. L.; Russell, S. E.; Worthington,
P. A. The synthesis of substituted pyridylpyrimidine fungicides
using palladium-catalysed cross-coupling reactions. Tetrahedron
Lett. 2000, 41, 1653-1656.
(21) Chen, C.; Dagnino, R., Jr.; McCarthy, J. R. A convenient
synthetic method for trisubstituted s-triazines. J. Org. Chem.
1995, 60, 8428-8430.
(22) Hughes, J. L.; Liu, R. C.; Enkoji, T.; Smith, C. M.; Bastian, J.
W.; Luna, P. D. Cardiovascular activity of aromatic guanidine
compounds. J. Med. Chem. 1975, 18, 1077-1088.
(23) Lohse, O. Improved large-scale preparation of 4-iodopicolinic
acid. Synth. Commun. 1996, 26, 2017-2025.
(24) Kuo, G.-H.; Connolly, P.; Prouty, C.; DeAngelis, A.; Wang, A.;
Jolliffe, L.; Middleton, S.; Emanuel, S. Preparation of pyrazines
as modulators of vascular endothelial growth factor (VEGF)
receptor tyrosine kinase. WO 200224681 A2 20020328. CAN
136: 279477.
(25) Sato, N.; Fujii, M. Studies on pyrazines. 29[1]. High regioselec-
tive synthesis of chloropyrazines from 3-substituted pyrazine
1-oxide. J. Heterocycl. Chem. 1994, 31, 1177-1180.
(26) Monaco, E. A., III; Vallano, M. L. Cyclin-dependent kinase
inhibitors: cancer killers to neuronal guardians. Curr. Med.
Chem. 2003, 10, 367-379.
(27) (a) CGP-60474 exhibits lower potency at CDK2 (IC50 ) 50-80
nM) and moderate potency at CDK4 (IC50 ) 700 nM). Ruetz, S.;
Fabbro, D.; Zimmermann, J.; Meyer, T.; Gray, N. Chemical and
biological profile of dual Cdk1 and Cdk2 inhibitors. Curr. Med.
Chem.: Anti-Cancer Agents 2003, 3(1), 1-14. (b) Zimmermann,
J. Pharmacologically active pyridine derivatives and processes
for the preparation thereof. PCT Int. Pat. WO 9509853 1995.
(28) Kuo, G.-H.; Wang, A.; Emanuel, S.; DeAngelis, A.; Zhang, R.;
Connolly, P. J.; Murray, W. V.; Gruninger, R. H.; Sechler, J.;
Fuentes-Pesquera, A.; Johnson, D.; Middleton, S. A.; Jolliffe, L.;
Chen, X. Synthesis and Discovery of Pyrazine-Pyridine Bihet-
eroaryl as a Novel Series of Potent Vascular Endothelial Growth
Factor Receptor-2 Inhibitors. J. Med. Chem. 2005, 48, 1886-
1900.
(9) Dasmahapatra, G. P.; Didolkar, P.; Alley, M. C.; Ghosh, S.;
Sausville, E. A.; Roy, K. K. In vitro combination treatment with
perifosine and UCN-01 demonstrates synergism against prostate
(PC-3) and lung (A549) epithelial adenocarcinoma cell lines. Clin.
Cancer Res. 2004, 10 (15), 5242-5252.
(10) Grosios, K. UCN-01 Kyowa Hakko Kogyo Co. Curr. Opin. Invest.
Drugs 2001, 2, 287-297.
(29) Schulze-Gahmen, U.; De Bondt, H. L.; Kim, S. H. High-resolution
crystal structures of human cyclin-dependent kinase 2 with and
without ATP: bound waters and natural ligand as guides for
inhibitor design. J. Med. Chem. 1996, 39, 4540.
(30) (a) Bain, J.; McLauchlan, H.; Elliott, M.; Cohen, P. The specifici-
ties of protein kinase inhibitors: an update. Biochem. J. 2003,
371, 199-204. (b) Davies, S. P.; Reddy, H.; Caivano, M.; Cohen,
P. Specificity and mechanism of action of some commonly used
protein kinase inhibitors. Biochem. J. 2000, 351, 95-105. (c) The
10-fold and 7-fold lower IC50 value obtained by UBI vs J & J at
CDK1 (0.002 vs 0.021 µM) and GSK-3â (0.003 vs 0.020 µM) may
be due to differences in assay conditions used, those include,
peptide substrate, ATP concentration, assay format, enzyme
construct, and the amount of enzyme present in the assay.
(31) Mettey, Y.; Gompel, M.; Thomas, V.; Garnier, M.; Leost, M.;
Ceballos-Picot, I.; Noble, M.; Endicott, J.; Vierfond, J.-M.; Meijer,
L. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study,
crystal structure in complex with CDK2, enzyme selectivity, and
cellular effects. J. Med. Chem. 2003, 46, 222-236.
(32) (a) Gray, N.; Wodicka, L.; Thunnissen, A. M.; Norman, T.; Kwon,
S.; Espinoza, F. H.; Morgan, D. O.; Barnes, G.; Leclerc, S.; Meijer,
L.; Kim, S. H.; Lockhart, D. J.; Schultze, P. Exploiting chemical
libraries, structure, and genomics in the search for new kinase
inhibitors. Science 1998, 281, 533-538. (b) Meijer, L. Chemical
inhibitors of cyclin-dependent kinases. Trends Cell Biol. 1996,
6, 393-397.
(11) McClue, S. J.; Blake, D.; Clarke, R.; Cowan, A.; Cummings, L.;
Fischer, P. M.; MacKenzie, M.; Melville, J.; Stewart, K.; Wang,
S.; Zhelev, N.; Zheleva, D.; Lane, D. P. In vitro and in vivo
antitumor properties of the cyclin dependent kinase inhibitor
CYC202 (R-roscovitine). Int. J. Cancer 2002, 102(5), 463-468.
(12) Dana, G.; Vivette, D.; Tearina, C. T.; Anna, B.; Athos, G.-B.;
Gelman, I. H.; Nelson, P. J. Reversal of collapsing glomerulopa-
thy in mice with the cyclin-dependent kinase inhibitor CYC202.
J. Am. Soc. Nephrol. 2004, 15, 1212-1222.
(13) Misra, R. N.; Xiao, H. Y.; Kim, K. S.; Lu, S.; Han, W. C.; Barbosa,
S. A.; Hunt, J. T.; Rawlins, D. B.; Shan, W.; Ahmed, S. Z.; Qian,
L.; Chen, B. C.; Zhao, R.; Bednarz, M. S.; Kellar, K. A.; Mulheron,
J. G.; Batorsky, R.; Roongta, U.; Kamath, A.; Marathe, P.;
Ranadive, S. A.; Sack, J. S.; Tokarski, J. S.; Pavletich, N. P.;
Lee, F. Y.; Webster, K. R.; Kimball, S. D. N-(cycloalkylamino)-
acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2.
N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-
4- piperidinecarboxamide (BMS-387032), a highly efficacious and
selective antitumor agent. J. Med. Chem. 2004, 47, 1719-1728.
(14) Dittrich, C.; Dumez, H.; Calvert, H.; Hanauske, A.; Faber, M.;
Wanders, J.; Yule, M.; Ravic, M.; Fumoleau, P. Phase I and
pharmacokinetic study of E7070, a chloroindolylsulfonamide
anticancer agent, administered on a weekly schedule to patients
with solid tumors. Clin. Cancer Res. 2003, 9, 5195-5204.
(33) (a) Schultz, C.; Link, A.; Leost, M.; Zaharevitz, D. W.; Gussio,
R.; Sausville, E. A.; Meijer, L.; Kunick, C. The paullones, a series
of cyclin-dependent kinase inhibitors: synthesis, evaluation of
CDK1/cyclin B inhibition, and in vitro antitumor activity. J. Med.